Lilly is appealing a court loss over whether retatrutide counts as a biologic. A win could mean 12 years of exclusivity instead of 5 and a later Medicare price fight.
Recap by typeshit. Full story at The American Journal of Managed Care.
A lawyer named Jeff walks through how his side argues Ozempic, Wegovy and other semaglutide drugs may be linked to NAION, a serious form of sudden vision loss.
Stavros Nicolaou of the Pharmaceutical Task Group wants police to act. SAHPRA says it has seized products and opened criminal cases.
The physician group is pushing back on an FDA plan that would open interim access to unapproved peptides, and wants the White House to block it.
Investigators turned up a warehouse of empty pens and a farm building used as a drug factory, as counterfeit weight loss injection sellers grow more organized.
Forbes covers a World Health Organization warning against GLP-1 weight loss drugs for kids and explains the reasoning behind it.
Dr Kaydo notes the full phase 3 data was published September 29, 2026. Retatrutide is still investigational and not approved by the FDA.
Loading…